Keryx Biopharma (KERX) Prices 8.23M Offering at $8.49/Share

Article Related Press Releases (2) Related Articles (3) Stock Quotes (1) Comments (0)

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase 1,235,100 additional shares of common stock. We intend to use the net proceeds from the sale of our common stock to fund pre-launch/launch inventory build-up and select pre-commercial/commercial activities related to Zerenex, and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager in the offering. The co-managers for the offering are Barclays Capital Inc., Citigroup, Oppenheimer & Co. Inc., Stifel Nicolaus Weisel, JMP Securities LLC, Roth Capital Partners, LLC, Brean Capital, LLC and Ladenburg Thalmann & Co. Inc. Burrill Securities LLC, Dawson James Securities, Inc., Maxim Group LLC, MLV & Co. LLC and Trout Capital LLC are acting as advisors to the company.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
• Ebix, Inc. (EBIX), Goldman (GS) Terminate Merger
• United Airlines (UAL) Upgrades, Adds Orders for Airbus A350-1000 Aircraft

Create E-mail Alert Related Categories

Corporate News, Equity Offerings

Related Entities

Stifel Nicolaus, JPMorgan, Citi, Roth Capital, JMP Securities, Barclays, Maxim Group, Ladenburg Thalmann Financial Services

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?